| Amanda L Strosahl, MD | |
|
1836 South Ave, La Crosse, WI 54601-5429 | |
| (608) 782-7300 | |
| Not Available |
| Full Name | Amanda L Strosahl |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Location | 1836 South Ave, La Crosse, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063416857 | NPI | - | NPPES |
| 31556800 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 28710 (Wisconsin) | Primary |
| Entity Name | Gundersen Clinic Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
A national survey has found that after a long, slow downward trend alcohol-impaired driving has recently increased significantly. From 1993 to 1997 the estimated annual number of episodes of alcohol-impaired driving (AID) declined at a rate of a little more than one percent per year, from 123 million to 116 million. From 1997 to 1999, however, it increased 37 percent, from 116 million to 159 million. It stayed at that increased rate in 2002.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest a new drug called carfilzomib could become an important new option for patients whose myeloma stops responding to other therapies.
Mission Pharmacal announced today that it will partner with the March of Dimes to distribute healthy pregnancy and healthy baby education materials to more than 15,000 obstetricians and gynecologists nationwide to help more babies be born healthy.
WideMed, a leading company engaged in the research, development and sale of innovative products for the growing bio-medical signal diagnostics and treatment market, announced today that the U.S. Food and Drug Administration has granted its home sleep monitoring device, Morpheus Ox, clearance to market in the United States for cardiac patient population.
› Verified 7 days ago
| Entity Name | Gundersen Lutheran Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376593442 PECOS PAC ID: 2163331414 Enrollment ID: O20130619000254 |
News Archive
A national survey has found that after a long, slow downward trend alcohol-impaired driving has recently increased significantly. From 1993 to 1997 the estimated annual number of episodes of alcohol-impaired driving (AID) declined at a rate of a little more than one percent per year, from 123 million to 116 million. From 1997 to 1999, however, it increased 37 percent, from 116 million to 159 million. It stayed at that increased rate in 2002.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest a new drug called carfilzomib could become an important new option for patients whose myeloma stops responding to other therapies.
Mission Pharmacal announced today that it will partner with the March of Dimes to distribute healthy pregnancy and healthy baby education materials to more than 15,000 obstetricians and gynecologists nationwide to help more babies be born healthy.
WideMed, a leading company engaged in the research, development and sale of innovative products for the growing bio-medical signal diagnostics and treatment market, announced today that the U.S. Food and Drug Administration has granted its home sleep monitoring device, Morpheus Ox, clearance to market in the United States for cardiac patient population.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda L Strosahl, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Amanda L Strosahl, MD 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 |
News Archive
A national survey has found that after a long, slow downward trend alcohol-impaired driving has recently increased significantly. From 1993 to 1997 the estimated annual number of episodes of alcohol-impaired driving (AID) declined at a rate of a little more than one percent per year, from 123 million to 116 million. From 1997 to 1999, however, it increased 37 percent, from 116 million to 159 million. It stayed at that increased rate in 2002.
Central to the study is FXO6, a peptide developed and patented by Austro-American company Fibrex Medical. Fibrex will now test the tolerability and pharmacokinetics of FX06 in humans. The peptide reduces inflammatory responses of the heart muscle that can arise after treatment for a myocardial infarction. Tests will begin immediately on the first - healthy - subjects at the Vienna General Hospital.
The International Myeloma Foundation, the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today said promising data suggest a new drug called carfilzomib could become an important new option for patients whose myeloma stops responding to other therapies.
Mission Pharmacal announced today that it will partner with the March of Dimes to distribute healthy pregnancy and healthy baby education materials to more than 15,000 obstetricians and gynecologists nationwide to help more babies be born healthy.
WideMed, a leading company engaged in the research, development and sale of innovative products for the growing bio-medical signal diagnostics and treatment market, announced today that the U.S. Food and Drug Administration has granted its home sleep monitoring device, Morpheus Ox, clearance to market in the United States for cardiac patient population.
› Verified 7 days ago
Mary K Frohnauer, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-775-2021 | |
Derek A Hupp, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Allen C. Foster, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Padmavathi Mali, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Emily Catherine Dolan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Blake Donald Jordan, DO Internal Medicine Medicare: Medicare Enrolled Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 | |
Adie D Harbin Iii, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1836 South Ave, La Crosse, WI 54601 Phone: 608-782-7300 |